Research

Caution is warranted with the use of antiseizure medications in the context of COVID-19 illness.

This neurology update focuses on mental well-being of people with epilepsy and their caregivers during the COVID-19 pandemic.

This is an interesting work elucidating for the first time a role for ataxin-1 (ATXN1) mutation, traditionally linked to spinocerebellar ataxia-type 1 (SCA1), in the pathogenesis of Experimental Autoimmune Encephalomyelitis (EAE), the rodent model for Multiple Sclerosis (MS)

The International Restless Legs Syndrome Study Group task force found sufficient evidence to formulate diagnostic criteria for pediatric clinical entity designated “restless sleep disorder”.

For December 2020, we have selected the following two papers: Zhang Q et al. ''COVID-19 case fatality and Parkinson’s disease'' and Bsteh G, et al. ''Multiple sclerosis and COVID-19: how many are at risk?''

For December 2020, we have selected the following paper: Deuschl et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017

Headache medication and the COVID-19 pandemic by Headache Scientific Panel

COVID‐19 and Headache: A Primer for Trainees by Headache Scientific Panel

Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia

The Second Pilot of the CoCoCare Course Has Started!

COVID-19 Associated Ischemic Stroke and Hemorrhagic Stroke: Incidence, Potential Pathological Mechanism, and Management

The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries

Ischemic Stroke Occurs Less Frequently in Patients With COVID-19 A Multicenter Cross-Sectional Study

EXPRESS: Stroke in COVID-19: a systematic review and meta-analysis